US20110097310A1 - Anti-aging or antioxidant composition containing plant stem cell line derived from cambium of panax ginseng - Google Patents

Anti-aging or antioxidant composition containing plant stem cell line derived from cambium of panax ginseng Download PDF

Info

Publication number
US20110097310A1
US20110097310A1 US12/997,858 US99785809A US2011097310A1 US 20110097310 A1 US20110097310 A1 US 20110097310A1 US 99785809 A US99785809 A US 99785809A US 2011097310 A1 US2011097310 A1 US 2011097310A1
Authority
US
United States
Prior art keywords
cell line
cambium
aging
extract
derived
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/997,858
Other languages
English (en)
Inventor
Mi Ok Jang
Min Jung Lim
Il Seok Oh
Dae Hee Lee
Eun Kyong Lee
Young Woo Jin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Unhwa Corp
Original Assignee
Unhwa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unhwa Corp filed Critical Unhwa Corp
Assigned to UNHWA CORPORATION reassignment UNHWA CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: JANG, MI OK, JIN, YOUNG WOO, LEE, DAE HEE, LEE, EUN KYONG, LIM, MIN JUNG, OH, IL SEOK
Publication of US20110097310A1 publication Critical patent/US20110097310A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • A61K2800/522—Antioxidants; Radical scavengers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/004—Aftersun preparations

Definitions

  • the present invention relates to an anti-aging or antioxidant composition containing, as an active ingredient, any one or more of a cell line derived from the cambium of Panax ginseng, including wild ginseng and ginseng, an extract thereof, a lysate thereof and a culture thereof.
  • the useful components are secondary metabolites that are produced secondarily during normal metabolic processes and accumulated at intracellular specific sites. These useful components are receiving increasing attention, because they serve to defend plants from microorganisms or external animals from biochemical and ecological viewpoint and are advantageous in terms of physiological activity. Secondary metabolites that are produced by plants include alkaloids, flavonoids, carotenoids, glycosides, terpenoids, etc.
  • cosmetic products containing useful components derived from plants include: a whitening cosmetic composition containing mulberrin isolated from Morus alba (Korean Patent Registration No. 25582), a cosmetic composition containing Alpinia Katsumadai extract (Korean
  • Patent Registration No. 295875 a cosmetic composition for preventing skin aging containing ginseng extract
  • a cosmetic composition for reducing wrinkles containing Ecklonia Cava a cosmetic composition for reducing wrinkles containing Ecklonia Cava
  • various cosmetic products have been developed which contain extracts of various plants, including chestnut bark, Xanthii fructus, gourd, Caesapinia sappan L., Giant knotweed, mallow, peppermint, Alnus japonica, herb, Birch, Pora cocos, Pomegranate, Willow bark, mung beans, rose, etc.
  • Such useful components derived from plants are secondary metabolites which are extracted directly from plants, because the biosynthetic pathways thereof are complex.
  • the skin is a primary defense barrier of the human body, which functions to protect various organs in the body from changes in temperature and humidity, and external environmental stimuli such as UV and pollutants, and plays an important role in maintaining homeostasis in vivo.
  • UV light, excessive physical and chemical stimuli from the external environment, stresses, nutritional deficiency and the like deteriorate the normal function of the skin and accelerate skin aging phenomena such as firmness loss, keratinization and wrinkle formation and the like.
  • cosmetics containing physiologically active substances obtained from various animals, plants and microorganisms so as to maintain the intrinsic function of the skin and activate skin cells, thus effectively suppressing skin aging.
  • cosmetic raw materials according to the prior art have various problems in that they mostly have insufficient effects or cause skin side effects.
  • the present inventors have made many efforts to develop natural material-derived compositions which have minimized side effects compared to existing anti-aging agents and antioxidants and have excellent anti-aging and antioxidant effects.
  • the present inventors have found that a homogeneous cell line derived from the cambium of Panax ginseng, a lysate thereof, an extract thereof or a culture thereof have excellent inhibitory effects against aging and oxidation, thereby completing the present invention.
  • the present invention provides an anti-aging or antioxidant composition containing any one or more of a cell line, which is derived from the cambium of Panax ginseng and has the following characteristics, an extract thereof, a lysate thereof and a culture thereof:
  • the present invention also provides an anti-aging cosmetic composition containing any one or more of said cell line, an extract thereof, a lysate thereof and a culture thereof.
  • the present invention also provides an anti-aging or antioxidant functional food containing any one or more of said cell line, an extract thereof, a lysate thereof and a culture thereof.
  • FIG. 1 is a set of photographs showing a process of deriving a cell line according to the present invention, and a cell line derived from the cambium of wild ginseng.
  • FIG. 2 is a graphic diagram showing the results of treating normal human skin fibroblasts (NHF) with various concentrations of an extract of a wild ginseng cambium-derived homogenous cell line of the present invention or a culture medium of the cell line and examining whether the extract or culture medium of the cell line is cytotoxic for the fibroblasts.
  • wet wet cells of ginseng
  • dry dry cells of ginseng
  • media cultured medium of ginseng cells
  • E1 elicitation-1 stage
  • E2 elicitation-2 stage
  • G growth stage.
  • FIG. 3 is a graphic diagram showing the results of treating normal human skin fibroblasts (NHF) with various concentrations of an extract of a wild ginseng cambium-derived homogenous cell line or a culture medium of the cell line, culturing the fibroblasts in 0.5% FBS minimal essential medium, and examining the effect of the wild ginseng cambium-derived homogenous cell line extract or culture medium on the proliferation of the fibroblasts.
  • wet wet cells of ginseng
  • dry dry cells of ginseng
  • media cultured medium of ginseng cells
  • E1 elicitation-1 stage
  • E2 elicitation-2 stage
  • G growth stage.
  • FIG. 4 is a graphic diagram showing the results of treating normal human skin fibroblasts (NHF) with various concentrations of an extract of a wild ginseng cambium-derived homogenous cell line or a culture medium of the cell line, treating the fibroblasts with UVB radiation, and examining whether an increase in MMP-1 expression caused by UVB radiation is inhibited by the wild ginseng cambium-derived homogenous cell line extract or culture medium.
  • wet wet cells of ginseng
  • dry dry cells of ginseng
  • media cultured medium of ginseng cells
  • E1 elicitation-1 stage
  • E2 elicitation-2 stage
  • G growth stage
  • RA retinoic acid
  • FIG. 5 is a graphic diagram showing the results of treating normal human skin fibroblasts (NHF) with various concentrations of an extract of a wild ginseng cambium-derived homogenous cell line or a culture medium of the cell line, treating the fibroblasts with UVB radiation, and examining whether an increase in reactive oxygen caused by UVB radiation is inhibited by the wild ginseng cambium-derived homogenous cell line extract or culture medium.
  • wet wet cells of ginseng
  • dry dry cells of ginseng
  • media cultured medium of ginseng cells
  • E1 elicitation-1 stage
  • E2 elicitation-2 stage
  • G growth stage
  • RA retinoic acid
  • FIG. 6 is a graphic diagram showing the effect of an extract of a wild ginseng cambium-derived homogenous cell line or a culture medium of the cell line on the inhibition of MMP-1 production when inducing MMP-1 by UV radiation.
  • FIG. 7 is a graphic diagram showing the effect of a wild ginseng cambium-derived homogenous cell line extract or culture medium of the present invention on the removal of reactive oxygen species caused by UV radiation.
  • the term “cambium” refers to a tissue that thickens the stem and root to allow the plant to grow volumetrically. It was reported that when the cambium, a meristem where the most active cell division occurs, is used as an explant for plant tissue culture, rapid and mass production of cells is possible (Korean Patent Registration No. 10-0533120).
  • lysate refers to a cell lysate obtained by disrupting cells through a chemical method with, for example, a detergent, or a physical method.
  • extract of a cell line refers to a substance obtained by dissolving cells in a solvent and isolating the substance, and the extract can be concentrated through distillation or evaporation.
  • culture medium of the cell line refers to a cell medium from which cells have been removed after culturing the cells.
  • culture of the cell line refers to a material containing a culture medium and/or a cultured cell line, wherein the cultured cell line is intended to include a cell line which differentiates under culture conditions or which have improved ability to produce and/or secrete useful substances.
  • the term “innately undifferentiated” means that cells are not present in an undifferentiated state through a dedifferentiation process, but are originally maintained in a pre-differentiated state.
  • the present invention provides an anti-aging or antioxidant composition containing, as an active ingredient, any one or more of a cell line derived from the cambium of Panax ginseng, a lysate thereof, an extract thereof and a culture thereof.
  • Panax ginseng includes wild ginseng or ginseng (Lian M. L. et al., J. Plant Biology, 45: 201, 2002; Han J. Y. et al., J. Plant Biology, 49:26, 2006; Teng W. L. et al., Tissue and Organ Culture, 68:233, 2002).
  • the wild ginseng or ginseng includes outdoor-cultivated ginseng or tissue-cultured ginseng (adventitious root and adventitious root-derived cell line).
  • the Panax ginseng cambium-derived cell line according to the present invention has the following characteristics: (a) it is in an innately undifferentiated state; (b) it is a homogeneous cell line; and (c) it is morphologically characterized by a number of vacuoles.
  • the Panax ginseng cambium-derived cell line according to the present invention is additionally characterized in that: (a) it is present as single cells during suspension culture; (b) it has low sensitivity to shear stress in a bioreactor compared to cell lines derived from tissues other than the cambium of Panax ginseng, and (c) it has a higher growth rate than those of cell lines derived from tissues other than the cambium of Panax ginseng and is cultured stably.
  • the cell line according to the present invention is obtained using an isolation method comprising the steps of: (a) obtaining storage root tissue containing the cambium of Panax ginseng; (b) applying osmotic stress to the obtained cambium-containing storage root tissue, and then culturing the cambium-containing storage root tissue in a IAA (Indole-3-acetic acid)- or IBA (Indole-3-butyric acid)-containing medium, thereby inducing a cambium-derived cell line; and (c) collecting the induced cambium-derived cell line.
  • IAA Indole-3-acetic acid
  • IBA Indole-3-butyric acid
  • step (b) of the inventive method the application of osmotic stress is carried out in order to induce the cell line specifically in the cambium.
  • it is carried out before culturing the tissue in the IAA- or IBA-containing medium, such that general tissues (i.e., cortex, phloem, xylem and pith) other than the cambium lose the ability to divide, and thus become necrotic when they are treated with a cambial division-specific hormone such as IAA or IBA.
  • the osmotic agent is used in an amount of 0.5-2M, and the osmotic stress is applied in a cold state or at room temperature for 16-24 hours, and then removed.
  • the scope of the present invention is not limited thereto, because the concentration, treatment time and temperature of the osmotic agent may vary depending on the kind of plant and the state of tissue.
  • the IAA or IBA is preferably contained in an amount of 0.1 ⁇ 5 mg/l.
  • step (c) is carried out by proliferating the induced cambium-derived cell line in a medium containing one or more of 2,4-D (2,4-dichlorophenoxyacetic acid), picloram and IBA, and then collecting the cambium-derived cell line.
  • 2,4-D, picloram and IBA is preferably contained in an amount of 1-5 mg/L, and more preferably 2 mg/L.
  • the culture of the cell line is preferably obtained by additionally culturing the cell line in a medium, which, as elicitors, contains 3-5 wt % of raw sugar or sugar, and/or any one or more of methyl jasmonate, chitosan, phenylalanin, benzoic acid, ABA, salicylic acid and sodium acetate.
  • the medium preferably contains 3-5 wt % of raw sugar or sugar; and at least one substance selected from the group consisting of methyl jasmonate, fungal extract, bacterial extract, yeast extract, chitosan, glucomannan, glucan, phenylalanine, benzoic acid, salicylic acid, arachidonic acid, STS, mevalonalonate N-benzolyglycine, ABA, SNP, IPP, BHT, CCC, ethephon, hippuric acid, ammonium ceric nitrate, AgNO 3 , vanadyl sulfate, p-aminobenzoic acid, brassinosteroids, sodium alginate, and sodium acetate.
  • a culture obtained by treating the cell line with elicitors including UV radiation, heat, ethylene, an antifungal agent, an antibiotic, heavy metal salt and high-concentration salt, to apply physical and chemical stresses thereto.
  • the medium used in the present invention is a conventional medium for plant tissue culture, and examples thereof include, but are not limited to, N6 medium, SH medium, MS medium, AA medium, LS medium, B5 medium, WPM medium, LP medium, White medium, GD medium, DKW medium, DCR medium, etc.
  • the extract is preferably obtained using a solvent selected from the group consisting of distilled water, alcohol, acetone, DMSO (dimethyl sulfoxide), and mixed solvents thereof.
  • a solvent selected from the group consisting of distilled water, alcohol, acetone, DMSO (dimethyl sulfoxide), and mixed solvents thereof.
  • examples of the alcohol include alcohols having 1 to 5 carbon atoms, such as methanol and ethanol.
  • the extract may be obtained by fractionating the cell line sequentially with distilled water, methanol and acetone.
  • fibroblasts that synthesize collagen were treated with said cell line extract or culture medium and, as a result, it was found that the cell line extract and culture medium have an excellent effect on the proliferation of fibroblasts, suggesting that the cell line extract and culture medium of the present invention have the effect of increasing skin elasticity.
  • the cell line extract and culture medium of the present invention have the effect of inhibiting the expression of MMP-1 which degrades skin collagen to form skin wrinkles, suggesting that they have the effect of preventing and reducing wrinkles.
  • the cell line extract and culture medium of the present invention have the effect of inhibiting reactive oxygen species induced by UV radiation, suggesting that they have an antioxidant effect. Because it is widely known to those of ordinary skill in the art that compositions having antioxidant activity have an anti-aging effect, it is obvious that the composition according to the present invention has an anti-aging effect.
  • the cell line extract had an anti-aging effect and antioxidant activity.
  • the composition containing the cell line shows an anti-aging effect and antioxidant activity
  • the composition containing the cell line according to the present invention or a lysate thereof can also show an anti-aging effect and antioxidant activity.
  • An anti-aging or antioxidant composition containing any one or more of the cell line according to the present invention, an extract thereof, a lysate thereof and a culture thereof may be provided as a pharmaceutical composition containing any one or more of said cell line, a lysate thereof, an extract thereof and a culture thereof alone or in combination with at least one pharmaceutically acceptable carrier, excipient or diluent.
  • the cell line, a lysate thereof, an extract thereof or a culture medium thereof may be contained in a pharmaceutical composition in a pharmaceutically effective amount depending on disease and its severity, the patient's age, weight, health condition and sex, the route of administration and the period of treatment.
  • the term “pharmaceutically acceptable composition” refers to a composition that is physiologically acceptable and does not cause allergic reactions or similar reactions such as gastrointestinal disorder or vertigo, when administered to humans.
  • said carrier, excipient or diluent may include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, magnesium stearate and mineral oils.
  • the pharmaceutical composition may additionally contain fillers, anti-aggregating agents, lubricants, wetting agents, perfumes, emulsifiers and preservatives.
  • the pharmaceutical composition of the present invention may be formulated using a method well known in the art, such that it can provide the rapid, sustained or delayed release of the active ingredient after administration to mammals.
  • the formulation may be in the form of powders, granules, tablets, emulsions, syrups, aerosols, soft or hard gelatin capsules, sterile injection solutions, sterile powders, etc.
  • the present invention relates to an anti-aging cosmetic composition containing, as an active ingredient, any one or more of said Panax ginseng cambium-derived cell line, a lysate thereof, an extract thereof and a culture thereof.
  • the term “functional cosmetic product” refers to a cosmetic product, the functionality of which has been improved by adding thereto any one or more of the cell line according to the present invention, an extract thereof, a lysate thereof and a culture medium thereof.
  • the anti-aging cosmetic composition containing the cell line of the present invention, a lysate thereof, an extract thereof or a culture medium thereof may be used to prepare a functional cosmetic product.
  • the cosmetic composition of the present invention may contain conventional ingredients for cosmetics, in addition to the cell line or its lysate, extract or culture medium as an active ingredient.
  • the cosmetic composition may contain conventional auxiliaries such as antioxidants, stabilizers, solubilizing agents, vitamins, pigments and perfumes, as well as carriers.
  • the cosmetic composition of the present invention may be prepared into any formulations that are conventional in the art.
  • the cosmetic composition can be prepared into a formulation selected from the group consisting of skin lotion, milk lotion, nourishing cream, massage cream, nourishing essence, pack, makeup base, foundation, body oil, hair oil, shampoo, and rinse.
  • the cosmetic composition of the present invention which contains any one or more of the cell line of the present invention, an extract thereof, a lysate thereof and a culture thereof, has an antioxidant effect, and thus has the effects of eliminating free radicals generated in the skin and protecting intracellular antioxidant systems. Accordingly, the cosmetic composition of the present invention can exhibit the effects of preventing and delaying skin aging resulting from oxidation caused by the action of, for example, free radicals.
  • the present invention relates to an anti-aging or antioxidant functional food containing, as an active ingredient, any one or more of the Panax ginseng cambium-derived cell line, a lysate thereof, an extract thereof and a culture thereof.
  • the term “functional food” refers to a food, the functionality of which has been improved by adding thereto the cell line of the present invention, a lysate thereof, an extract thereof or a culture medium thereof.
  • FIG. 1( a ) shows the typical feature of wild ginseng used in the present invention.
  • the main root was purchased, and then washed with running water to remove earth or other contaminants from the surface thereof, and the surface of the main root was washed with a liquid detergent. Then, the main root was allowed to stand under running water.
  • the washed root tissue was placed in a sterilized flask in a clean bench and disinfected with 70% ethanol for a time ranging from about 30 seconds to about 1 minute. Then, it was rinsed with sterile water and treated with a disinfectant solution containing 1-1.5% sodium hypochlorite (Junsei, Japan) for about 5-15 minutes.
  • TWEEN 20 polyoxyethylenesorbitan monolaurate, Junsei, Japan
  • the tissue was rinsed 3-5 times with sterile water.
  • the disinfected main root was placed in antioxidant-containing BIM (browning inhibition medium) and shake-cultured for about 30 minutes to 1 hour. The cultured tissue was placed on sterile filter paper to remove water.
  • the salt is added in an amount corresponding to the total volume of BIM.
  • the material was placed in a dish containing an antioxidant-containing CS solution (cutting solution, Table 2) and peeled. Then, the material was cut into two equal parts, and each of the parts was cut to a size of 0.5-0.7 cm (width) ⁇ 0.5-0.7 cm (length) ⁇ 0.2-0.5 mm (thickness) in such a manner that each cut portion contained a cambium portion having active division ability.
  • “B” of FIG. 1( a ) shows the explant prepared by cutting the main root of the wild ginseng to the above size in such a manner that the explant contains the cambium.
  • the explant prepared in Example 1-1 was treated with osmotic stress in order to necrotize differentiated tissues (i.e., phloem, xylem, pith, etc.) and to allow only the meristem cambium to survive.
  • the cambium-containing explant was blotted onto a preculture medium (medium 1, Table 3) having filter paper laid thereon, and it was placed in a flask containing 1M sucrose solution (Duchefa, Netherland) and was treated with osmotic stress in a cold state for 16-24 hours. Then, the explant was treated in 0.05M sucrose solution for 5 minutes and in 0.1M sucrose solution for 5 minutes to remove the stress caused by the high-concentration sucrose. The cambium-containing explant from which the osmotic stress has been removed was placed on a preculture medium (medium 1) having filter paper laid thereon to remove moisture.
  • composition of preculture medium Composition mg/l mM Macroelements Ca(NO 3 ) 2 2.35 471.26 NH 4 NO 3 5 400 MgSO 4 •7H 2 O 1.5 180.54 K 2 SO 4 5.68 990 CaCl 2 •2H 2 O 0.65 72.5 KH 2 PO 4 1.25 170 ⁇ M Microelements MnSO 4 •4H 2 O 131.94 22.3 ZnSO 4 •7H 2 O 29.91 8.6 Na 2 MoO 4 •2H 2 O 1.03 0.25 H 3 BO 3 100.27 6.2 CuSO 4 •5H 2 O 1.0 0.25 FeNa-EDTA 100 36.7 Vitamin Glycine 26.64 2.0 myo-Inositol 554.94 100 Nicotinic acid 4.06 0.5 Pyridoxine-HCl 2.43 0.5 Thiamine-HCl 2.96 1.0
  • Example 1-2 In order to induce a cambium-derived homogeneous cell line having the cell division ability, the explant treated with osmotic stress in Example 1-2 was transferred to a cell line induction medium (medium 2, Table 4). The composition of the medium used is shown in Table 4 below. The transferred explant was cultured in a dark condition at 22 ⁇ 1° C.
  • the explant was cultured in a 2,4-D-containing medium, which was not the homogeneous cell line-induction medium and has been used in the conventional culture of Panax ginseng, including ginseng and wild ginseng. In this case, it was observed that the entire explant started to turn yellow after 7-10 days of the culture, and about 7-14 days therefrom, cells were induced throughout the whole cross section.
  • the medium used in the proliferation was an optimal medium (Table 7) for proliferation of the cambium-derived homogeneous cell line having to the ability to divide, which contained a basal salt composition (Table 6).
  • composition of optimal medium (medium) for the isolation and proliferation of cambium-derived homogeneous cell line having the ability to divide Component Concentration and condition Salt Full strength MS Sucrose 3% (w/v) 2,4-D(2,4-dichlorophenoxyacetic acid) 2 mg/L pH 5.8 Gelrite 0.3% (w/v) Ascorbic acid 100 mg/L Citric acid 150 mg/L
  • the wild ginseng cambium-derived homogeneous cell line was placed in a flask containing the liquid medium shown in Table 8. Then, the cell line was cultured in a rotating shaker at 100 rpm in a dark condition at 25 ⁇ 1° C. Herein, the subculture interval was set to 2 weeks, such that the cultured cells could always maintain high vitality in the exponential growth phase. Meanwhile, the ginseng cotyledon-derived callus was also cultured in medium 4 of Table 8, and the cultured callus was compared with the wild ginseng cambium-derived homogeneous cell line of the present invention.
  • the quantification of cell aggregation was observed under an optical microscope (biological microscope CX31, Olympus, Japan) and, as a result, it could be seen that, as shown in Table 9 below, more than 90% of cells of the cell lines according to the present invention were present as single cells during suspension culture. As shown in FIG. 1( b ), it could be observed that the cell line of the present invention was morphologically characterized by a large number of vacuoles and was in an undifferentiated state.
  • each of the ginseng cotyledon-derived callus and the wild ginseng cambium-derived cell line of the present invention was cultured in an airlift bioreactor (Sung-Won Cytec, Korea) having an internal volume of 3 L.
  • the medium used in the culture was the liquid medium shown in Table 8 and was maintained in a dark condition at 25 ⁇ 1° C.
  • the doubling time of the ginseng cotyledon-derived cell culture was 21 days in the flask and 28 days in the reactor.
  • the cambium-derived cell line according to the present invention showed about 3 to 5-fold higher growth rate compared to cell lines derived from other tissues, and when cultured in the reactor, the cambium-derived cell line according to the present invention showed 5 to 9-fold higher growth rate compared to cell lines derived from tissues other than the cambium. This is believed to be because cell viability of the heterogeneous cell line rapidly decreased due to growth ring production in the reactor, plant cell aggregation during culture, and the sensitivity of hard cell walls to shear stress.
  • the doubling time of the cambium-derived cell culture medium according to the present invention in the reactor was 3-4 days, which did not differ from that in the flask or was rather shortened compared to that in the flask.
  • the cambium-derived homogeneous cell culture medium formed a very small growth ring area in the bioreactor, and the ring on the inner wall was simply eliminated, when a simple stimulus was applied to the incubator to shake the medium.
  • the cell line of the present invention had low aggregation and contained a large number of vacuoles, and thus had low sensitivity to shear stress, such that cell viability did not decrease.
  • the cambium-derived cell line according to the present invention had low sensitivity to shear stress resulting from shaking in the bioreactor for scale-up culture, and thus could be produced rapidly in large amounts in the bioreactor. Accordingly, it could be seen that the cambium-derived cell line according to the present invention had 5 to 9-fold lower sensitivity to shear stress compared to cell lines derived from tissues other than the cambium.
  • the cell line which has been suspension-cultured for 14 days as described in Example 1-5, was divided into three groups for experiments.
  • the following cell lines were collected and subjected to subsequent tests: (1) the cell line (growth stage) suspension-cultured for 14 days, (2) a cell line (Elicitation 1), obtained by culturing the 14-day suspension-cultured cell line in a medium (containing sterile water, 3-5 wt % (g/L) raw sugar and 100 ⁇ M methyl jasmonate) in a dark condition for 14 days, and (3) a cell line (Elicitation 2), obtained by culturing the 14-day suspension-cultured cell in a medium (containing 100 ⁇ M methyl jasmonate) in a dark condition for 14 days.
  • a cell line (Elicitation 1) obtained by culturing the 14-day suspension-cultured cell line in a medium (containing ⁇ M methyl jasmonate) in a dark condition for 14 days
  • a cell line (Elicitation 2) obtained by culturing the 14-day suspension-cultured cell in a medium (containing 100 ⁇ M methyl jasmonate) in a dark
  • cytotoxicity test was performed in the following manner.
  • NHF (normal human fibroblast) cells used in the test were isolated from the fetal foreskin and cultured.
  • a medium used in the cell culture was prepared by adding 10% fetal bovine serum (FBS, Hyclone, Logan, Utah, USA), inactivated by heating at 56° C. for 30 minutes, 100 unit/ml penicillin, 100 ⁇ g/ml streptomycin and 300 ⁇ g/ml-glutamine, to DMEM medium (Invitrogen Gibco life tech. Vienna, Austria).
  • the cells were cultured in the above medium in a 5% CO 2 incubator at 37° C. at a relative humidity of 95%, and subcultured at 3 to 4-day intervals immediately before the cells would be fused with each other.
  • the NHF cells were used in the experiments of this Example and Examples 4 and 5 below.
  • the NHF(p5) cells normal human fibroblast cells
  • DMSO extracts and culture media of the wild ginseng cambium-derived cell line prepared in Example 2, at various concentrations (Wet and dry DMSO extracts of the wild ginseng calcium-derived cell line: ppm; and culture media of the cell line: %). Then, the cells were allowed to proliferate. As a control, cells, treated with neither the extract nor the culture medium, were used.
  • WST-1 solution was diluted 100-fold and added to each well of the plate, and after 2 hours, the absorbance of the plate was measured.
  • Extracts and the culture media did not show toxicity in the concentration ranges used in the experiment. Extracts or culture media showing a cell viability of 80% or more were determined to be non-toxic.
  • Extracts or culture media showing a cell viability of 80% or more were determined to be non-toxic.
  • “Elicitation 1” indicates a DMSO extract of the cell line of Example 1-6, treated with 3-5 wt % (g/L) of raw sugar and 100 ⁇ M of methyl jasmonate
  • “Elicitation 2” indicates a DMSO extract of the cell line of Example 1-6, treated with 100 ⁇ M of methyl jasmonate
  • “Growth” indicates a DMSO extract of the 14-day-suspension-cultured cell line (growth stage) of Example 1-6
  • “Media” indicates culture media removed during the preparation of the cell line extracts.
  • Normal human fibroblast cells (NHF cells) cultured in 3.5% FBS-containing DMEM (Doubecco's Modified Eagle's Media) medium were dispensed in a 96-well microtiter plate at density of 5,000 cells/well and starved for 24 hours. Then, the cells were treated for 48 hours with the DMSO extract or culture medium of the wild ginseng cambium-derived cell line, prepared in Example 2, in 0.5% FBS minimal essential media at various concentrations (wet and dry DMSO extracts of the wild ginseng calcium-derived cell line: ppm; and culture media of the cell line: %).
  • FBS-containing DMEM Doubecco's Modified Eagle's Media
  • WST-1 solution was diluted 100-fold and dispersed in the plates, and after 2 hours, 50 ⁇ l of 0.2% MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) solution was added to each well of the plate. Then, the cells were cultured at 37° C. for 4 hours, and the produced formazan was dissolved in DMSO (dimethyl sulfoxide). The absorbance of the dissolved formazan was measured at 570 nm using a microplate reader.
  • MTT 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide
  • test group treated with the wild ginseng cambium-derived cell line extract or culture medium was compared with the control treated with neither the extract nor the culture medium, and the results of the comparison are shown in Table 12 below.
  • 10% FBS indicates cells cultured in 10% FBS that is a nutrient medium concentration for maximal growth in animal cell culture
  • Control is a negative control group and indicates cells cultured in 0.5% FBS essential medium without adding the cell line extract or culture medium.
  • the cell line extract and culture medium according to the present invention had an effect on the proliferation of fibroblasts, unlike the control, and particularly, the freeze-dried cell line extract (Dry) had an excellent effect on the proliferation of fibroblasts.
  • the freeze-dried cell line extracts (Dry) in various growth stages were compared with each other, the extract of Elicitation 1 had the best effect on the proliferation of fibroblasts, and the cells of Elicitation 2 and the cells of Growth stage showed similar effects in the proliferation of fibroblasts.
  • the cell line extract according to the present invention has the effect of increasing skin elasticity.
  • NHF(p6) cells were dispensed in a 12-well plate at a density of 75,000 cells/well and starved for 24 hours. Then, the cells were radiated with 40 mJ of UVB and treated with varying concentrations of each of the samples for 48 hours. Then, an experiment was carried out using a kit (Amersham, RPN 2610). As a positive control, 10 ⁇ M retinoic acid was used.
  • the cell line extract and culture medium according to the present invention effectively inhibited the expression of MMP-1 compared to the negative control (Control UV), suggesting that they had the effects of preventing and reducing wrinkles.
  • the NHF(p6) cells were treated with 0.1% of each of the cell line culture media of Elicitation 1, treated with raw sugar and methyl jasmonate, and of Elicitation 2, treated only with methyl jasmonate, these cell line culture media showed a very excellent effect compared to retinoic acid known to have the strong effect on wrinkle reduction.
  • human keratinocyte HaCaT cells (German Cancer Research Institute, Heidelberg, Germany) were dispensed in a 96-well black plate at a density of 30,000 cells/well and treated with varying concentrations of each of the samples for 3 hours. After 3 hours, the plate was washed once with HBSS, each well was treated with 50 ⁇ M DCF and incubated at 37° C. for 20 minutes. After the plate had been washed twice with HBSS, the initial absorbance of the cells was measured using a luminator.
  • Control indicates a group treated with neither the sample nor UVB
  • UVB indicates a group treated only with UVB without adding the sample.
  • the cell line extract of Elicitation 1 showed an excellent antioxidant effect.
  • the cell line extract of Elicitation 2 and the cell line extract of Growth stage showed similar antioxidant effects.
  • the group treated with 50 ppm of the freeze-dried cell line extract of Elicitation 1 showed the most excellent antioxidant effect.
  • the ginsenoside components of wild ginseng extracts are effective in skin aging prevention and antioxidation.
  • the content of ginsenosides was measured. Specifically, the wild ginseng cambium-derived homogeneous cell line prepared in Example 2 and wild ginseng were freeze-dried, and 20 mg of the freeze-dried cell line was extracted in 600 ⁇ l of methanol for 1 hour. The extract was centrifuged and the supernatant was isolated.
  • the content of ginsenosides in the isolated extract was measured using HPLC, and the measured content was shown in comparison with standard Re, Rb1, Rb2 and Rd. Also, the culture medium of Elicitation 1 was filtrated using a 0.2- ⁇ m syringe filter, and the content of ginsenosides therein was measured using HPLC. The measured content was shown in comparison with standard Re, Rb1, Rb2 and Rd.
  • the cell line of Elicitation 2 showed the highest ginsenoside content, but ginsenoside content of the wild ginseng extract, a control group, was 167-fold higher than the ginsenoside content of the wild ginseng cambium-derived homogeneous cell line. Also, no ginsenoside was detected in the wild ginseng cambium-derived cell line of growth stage or in the cell line culture medium. This suggests that the skin anti-aging and antioxidant effects of the cell line extract and culture medium according to the present invention are not attributable to ginsenosides and that the cell line isolated according to the method of the present invention contains active ingredients that differ from those of conventional wild ginseng cells.
  • fibroblasts (MCTT, Korea) were seeded in a 24-well plate at a density of 2 ⁇ 10 4 cells/well and cultured for 12 hours to adhere to the culture plate. Then, the cells were starved in FBS-free medium for 12 hours. The cells were washed with DPBS buffer and irradiated with 100 mJ/cm 2 of UV at 365 nm.
  • the cells were treated with each of 1, 10 and 50 ppm of a DMSO extract (Elicitation 1) of the freeze-dried cell line of Example 2 (treated with 3-5 wt % (g/L) of raw sugar and 100 ⁇ M of methyl jasmonate) or with each of 0.05, 0.1 and 1 vol % of the culture medium of Example 2, in FBS-free medium for 24 hours.
  • positive control cells were treated with 1 ⁇ M of RA (retinoic acid), and additional control cells were treated with each of 1, 10 and 50 ppm of a DMSO extract of the freeze-dried wild ginseng root of Example 2.
  • each of the culture media was collected and centrifuged, and the amount of MMP-1 in the supernatant was determined by an ELISA assay (Amersham). The viability of the cells was measured using WST-1 solution and corrected.
  • the cell line extract according to the present invention showed MMP-1 inhibitory activities of about 55% (1 ppm), about 67% (10 ppm) and about 83%, and the cell line culture medium showed MMP-1 inhibitory activities of about 49% (0.05 vol %), about 63% (0.1 vol %) and 70% (1 vol %). Also, when the cells were treated with 10 ppm or 50 ppm of the cell line extract or with 0.1 vol % or 1 vol % of the culture medium, it was found that the cell line extract and the culture medium showed excellent anti-aging effects compared to the positive control RA known to have an excellent anti-aging effect.
  • the cell line extract and culture medium according to the present invention showed significantly excellent effects on the inhibition of MMP-1 expression compared to the control (the freeze-dried DMSO extract of the outdoor-cultivated wild ginseng root). Specifically, the MMP-1 inhibitory activity of the cell line extract was improved by 27-51% relative to that of the cultivated wild ginseng, and the MMP-1 inhibitory activity of the cell line extract was improved by 16-27%.
  • the cell line extract and culture medium according to the present invention showed very excellent anti-aging effects compared to RA known to have excellent anti-aging effects and wild ginseng extract, suggesting that the cell line extract and culture medium according to the present invention are particularly useful as anti-aging compositions.
  • human keratinocyte HaCaT cells (German Cancer Research Institute, Heidelberg, Germany) were cultured in 10% FBS-containing DMEM medium. The cells were seeded in 96-well plates at a density of 3 ⁇ 10 4 cells/well for 12 hours to adhere to the culture plate. Then, the cells were treated with each of 1, 10 and 50 ppm of a DMSO extract (Elicitation 1) of the freeze-dried cell line of Example 2 (treated with 3-5 wt % (g/L) of raw sugar and 100 ⁇ M of methyl jasmonate) or with each of 1, 5 and 10 vol % of the culture media of Example 2 in FBS-free DMEM medium for 3 hours.
  • a DMSO extract Edlicitation 1
  • positive control cells were treated with 10 mM NAC (N-acetyl-cysteine), and additional control cells were treated with each of 1, 10 and 50 ppm of a DMSO extract of the freeze-dried wild ginseng root of Example 2.
  • NAC N-acetyl-cysteine
  • the cells were washed with HBSS buffer and incubated with 50 ⁇ M F-DA (HBSS) at 37° C. for 20 minutes. Then, the cells were washed twice with HBSS buffer, 30 ⁇ l HBSS was added thereto, and the cells were radiated with 200 mJ/cm 2 of UV at 365 nm. Then, the cells were cultured at 37° C. for 2 hours and measured for fluorescence (excitation, 485 nm; emission, 535 nm; Infinite M-200, Tecan), and the cell viability was measured using WST-1 solution and corrected. The effect of each sample on the removal of reactive oxygen species was compared with the UV-non-radiated group whose fluorescence was taken as 100.
  • HBSS F-DA
  • the wild ginseng extract as the control showed an inhibitory activity of 17-26%, whereas the cell line extract and culture medium according to the present invention showed further increased inhibitory activities of 28-36% and 35-58%, respectively.
  • the cell line extract and culture medium according to the present invention had much more potent antioxidant effects than the cultivated wild ginseng extract.
  • 100 mg of the cell line extract prepared in Example 2 was mixed with 100 mg of maize starch, 100 mg of lactose and 2 mg of magnesium stearate, and the mixture was compressed into a tablet according to a conventional tableting method.
  • Example 1 1 g of the cell line prepared in Example 1 was mixed with 10 g of isomerized sugar, 5 g of mannitol and a suitable amount of purified water, and the mixture was prepared into 100 ml of a syrup formulation according to a conventional method.
  • Components wt % Formulation 1 Preparation of skin lotion Wild ginseng cell line 0.1 extract or culture medium thereof Glycerin 3 Butylene glycol 2 Propylene glycol 2 Carboxyvinyl polymer 0.1 PEG 12 Nonylphenyl ether 0.2 Polysorbate 80 0.4 Ethanol 10 Triethanolamine 0.1 Antiseptics, pigment, q.s.
  • Fragrance Purified water to 100 Formulation 5: Preparation of pack Wild ginseng cell line 5 extract or culture medium thereof Polyvinyl alcohol 13 Carboxymethylcellulose sodium 0.2 Glycerin 5 Allantoin 0.1 Ethanol 6 PEG 12 Nonylphenyl ether 0.3 Polysorbate 60 0.3 Antiseptics, pigment, q.s. Fragrance Purified water to 100
  • Example 2 200 mg of the cell line prepared in Example 1 was dissolved in 96 ml of water, and then 500 mg of vitamin C as a supplement, 1 g of each of citric acid and oligosaccharide as flavor enhancers and 0.05 g of sodium benzoate as a preservative were added thereto. Then, purified water was added thereto, thus preparing 100 ml of a functional beverage.
  • Example 2 200 mg of the cell line extract prepared in Example 2 was dissolved in 96 ml of water, and then 500 mg of vitamin C as a supplement, 1 g of each of citric acid and oligosaccharide as flavor enhancers and 0.05 g of sodium benzoate as a preservative were added thereto. Then, purified water was added thereto, thus preparing 100 ml of a functional beverage.
  • the composition according to the present invention has minimized side effects compared to existing anti-aging agents and antioxidants, and thus is safe for the skin. Also, the composition of the present invention shows an antioxidant effect of inhibiting reactive oxygen species caused by exposure to UV radiation that is the major cause of skin aging, and it can effectively reduce or inhibit aging-related factors. Thus, the composition of the present invention is useful for the prevention and inhibition of aging.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Medical Informatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Toxicology (AREA)
  • Cosmetics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
US12/997,858 2008-06-13 2009-06-12 Anti-aging or antioxidant composition containing plant stem cell line derived from cambium of panax ginseng Abandoned US20110097310A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20080056008 2008-06-13
KR10-2008-0056008 2008-06-13
PCT/KR2009/003176 WO2009151302A2 (ko) 2008-06-13 2009-06-12 산삼 또는 인삼을 포함한 인삼류의 형성층 유래 식물줄기세포주를 유효성분으로 함유하는 노화방지 또는 항산화용 조성물

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/003176 A-371-Of-International WO2009151302A2 (ko) 2008-06-13 2009-06-12 산삼 또는 인삼을 포함한 인삼류의 형성층 유래 식물줄기세포주를 유효성분으로 함유하는 노화방지 또는 항산화용 조성물

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/863,817 Continuation US9095532B2 (en) 2008-06-13 2013-04-16 Composition for anti-aging or antioxidant composition containing plant stem cell line derived from cambium or Panax ginseng including wild ginseng and ginseng as active components

Publications (1)

Publication Number Publication Date
US20110097310A1 true US20110097310A1 (en) 2011-04-28

Family

ID=41417270

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/997,858 Abandoned US20110097310A1 (en) 2008-06-13 2009-06-12 Anti-aging or antioxidant composition containing plant stem cell line derived from cambium of panax ginseng
US13/863,817 Active US9095532B2 (en) 2008-06-13 2013-04-16 Composition for anti-aging or antioxidant composition containing plant stem cell line derived from cambium or Panax ginseng including wild ginseng and ginseng as active components

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13/863,817 Active US9095532B2 (en) 2008-06-13 2013-04-16 Composition for anti-aging or antioxidant composition containing plant stem cell line derived from cambium or Panax ginseng including wild ginseng and ginseng as active components

Country Status (10)

Country Link
US (2) US20110097310A1 (ru)
EP (1) EP2308462A2 (ru)
JP (1) JP5572786B2 (ru)
KR (1) KR101126315B1 (ru)
CN (1) CN102159182B (ru)
AU (1) AU2009258386B2 (ru)
BR (1) BRPI0909876A2 (ru)
CA (1) CA2732058C (ru)
RU (1) RU2500386C2 (ru)
WO (1) WO2009151302A2 (ru)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100233813A1 (en) * 2007-09-21 2010-09-16 Unhwa Corporation Plant stem cell line derived from cambium of herbaceious plant with storage root and method for isolating the same
US20110039312A1 (en) * 2005-10-31 2011-02-17 Unhwa Isolated population of plant single cells and method of preparing same
US20110217273A1 (en) * 2008-09-30 2011-09-08 Unhwa Corporation Composition for Preventing or Treating AIDS Containing Plant Stem Cell Line Derived from Cambium of Panax Ginseng Including Wild Ginseng or Ginseng as Active Ingredient
US9095532B2 (en) 2008-06-13 2015-08-04 Unhwa Corporation Composition for anti-aging or antioxidant composition containing plant stem cell line derived from cambium or Panax ginseng including wild ginseng and ginseng as active components
US9289457B2 (en) 2008-08-14 2016-03-22 Unhwa Coproration Composition for preventing or treating liver diseases, containing plant stem cell lines derived from the cambium of Panax ginseng including mountain ginseng or ginseng as active ingredient
US10463603B2 (en) 2012-01-05 2019-11-05 L'oreal Cosmetic use of dedifferentiated plant cells
CN110870562A (zh) * 2018-08-29 2020-03-10 株式会社爱茉莉太平洋 用于增强皮肤弹性或改善皮肤皱纹的包含人参细胞裂解物的组合物

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007052876A1 (en) 2005-10-31 2007-05-10 Unhwa Stability of secondary metabolite mass production through syncronized plant cell cultures
JP2012527889A (ja) * 2009-05-26 2012-11-12 株式会社ウンファ イチョウ科の形成層由来植物幹細胞及びその分離方法
KR101233987B1 (ko) * 2010-03-18 2013-02-18 동국대학교 산학협력단 발효홍삼의 제조방법
KR101233991B1 (ko) * 2010-03-18 2013-02-18 동국대학교 산학협력단 발효홍삼의 제조방법
CN103841956B (zh) * 2011-03-27 2016-11-09 奥麒化工有限公司 调节表观遗传dna甲基化以导致细胞采取与年轻细胞相关的dna甲基化模式
KR101321011B1 (ko) * 2011-11-30 2013-10-23 주식회사 엘지생활건강 피부결 개선용 조성물
FR3007982B1 (fr) 2013-07-05 2015-08-21 Oreal Stabilisation des cellules dedifferenciees de rose.
US10646528B2 (en) 2014-08-22 2020-05-12 Wellkey Holdings Limited Method for preparing extract of genus Panax including wild ginseng or ginseng, or cambial meristematic cells derived from genus panax or extract thereof containing rare ginsenosides in high quantity
CN104498425B (zh) * 2014-11-28 2016-03-02 广州赛莱拉干细胞科技股份有限公司 雪莲干细胞的分离培养方法及在制备抗衰老产品中的应用
KR101836354B1 (ko) * 2015-03-09 2018-03-09 주식회사 한국화장품제조 산삼배양근 오일을 유효성분으로 포함하는 화장료 조성물
EP3135341B1 (en) 2015-08-27 2019-02-20 Latvijas Universitate Cosmetic skin whitening compositions containing extracts derived from in vitro propagated hypericum hirsutum
CN105748343B (zh) * 2016-02-25 2018-06-15 广州市科玮生物技术有限公司 一种天然植物提取物组合物及其在化妆品中的应用
CN105661240A (zh) * 2016-03-10 2016-06-15 浙江博士园生物技术有限公司 一种北虫草饮料及其制备方法
CN105919886A (zh) * 2016-06-13 2016-09-07 广东万海细胞生物科技有限公司 一种速效修复皱纹的乳液及其制备方法
CN105963211A (zh) * 2016-07-02 2016-09-28 广东万海细胞生物科技有限公司 一种深层护理面膜膏及其制备方法
KR101759650B1 (ko) * 2017-04-03 2017-07-19 연세대학교 산학협력단 오시멘(Ocimene) 또는 이의 염을 유효성분으로 함유하는 피부주름 개선, 보습, 탄력증진, 각질제거, 홍반억제 또는 피부광노화 개선용 조성물
CN107616964A (zh) * 2017-09-15 2018-01-23 广州赛莱拉干细胞科技股份有限公司 一种高丽参干细胞护肤组合物及其制备方法
CN107789306A (zh) * 2017-10-31 2018-03-13 广州赛莱拉干细胞科技股份有限公司 一种高丽参干细胞提取物滋润保湿护肤组合物及其制备方法
KR102655941B1 (ko) * 2018-08-13 2024-04-11 (주)아모레퍼시픽 신규 진세노사이드를 포함하는 항산화 조성물
KR102187618B1 (ko) * 2018-11-01 2020-12-07 (주)아모레퍼시픽 수크로스, 인돌-3-아세트산 및 로즈힙 열매 추출물의 혼합물을 포함하는 피부 외용제 조성물
FR3105259B1 (fr) 2019-12-19 2022-03-11 Oreal Cellules végétales dédifférenciées non élicitées deLavandula angustifolia, ses extraits et ses utilisations cosmétiques
CN114053204A (zh) * 2021-11-01 2022-02-18 上海普瑞康企业发展有限公司 一种含长白山野山参细胞水提取物的抗衰霜
CN117362110B (zh) * 2023-11-02 2024-02-13 烟台众德集团有限公司 一种基于壳寡糖的缓释肥料及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61173774A (ja) * 1985-01-26 1986-08-05 Nissho Kisetsu:Kk 生薬成分を含む生物組織の培養法
JPS6239529A (ja) * 1985-08-13 1987-02-20 Nitto Electric Ind Co Ltd 薬用人参エキスの製造方法
FR2647342B1 (fr) * 1989-05-23 1994-05-27 Sanofi Sa Composition cosmetique s'opposant au vieillissement de la peau
DE4028622C2 (de) * 1990-09-08 1994-01-27 Suwelack Nachf Dr Otto Verfahren zum Herstellen von Kollagenschwämmen
JPH10182412A (ja) * 1996-12-27 1998-07-07 Kose Corp 外用剤
KR100253842B1 (ko) 1997-09-12 2000-07-01 유상옥 멀베린을 함유하는 미백화장료
KR19990057560A (ko) * 1997-12-30 1999-07-15 박명규 인삼의 부위별 유해산소제거효소 함량증가 효과 검증방법 및 항 산화 효능을 갖는 인삼 엑스
KR100361433B1 (ko) 1998-05-28 2003-01-24 주식회사 태평양 인삼추출물을함유하는피부노화방지용화장료조성물
KR100295875B1 (ko) 1998-11-07 2001-11-14 정찬복 초두구추출물을함유하는화장료
EP1295893A4 (en) * 2000-05-31 2005-10-26 Japan Science & Tech Agency GINSENOSIDES FOR PROMOTING SKIN WEBERENEGENERATION
KR100365071B1 (ko) * 2000-12-28 2002-12-18 주식회사 태평양 인삼 어글리콘을 함유하는 피부 노화방지용 화장료 조성물
KR100440193B1 (ko) 2001-01-08 2004-07-12 김기창 탄성밴드 제조방법 및 그 탄성밴드
KR100479803B1 (ko) * 2002-04-08 2005-03-30 홍림통산(주) 약효가 증가된 특수가공처리 인삼 추출물을 함유하는뇌졸증의 예방 및 치료를 위한 조성물
KR100533120B1 (ko) 2003-06-16 2005-12-14 주식회사 운화 바이오텍 형성층을 이용한 식물세포배양 방법
WO2007052876A1 (en) * 2005-10-31 2007-05-10 Unhwa Stability of secondary metabolite mass production through syncronized plant cell cultures
BRPI0909876A2 (pt) 2008-06-13 2020-09-01 Unhwa Corporation composição, cosmético e alimento funcional anti-envelhecimento ou antioxidante contendo linhagem de células de caule vegetal derivada de câmbio de panax ginseng

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110039312A1 (en) * 2005-10-31 2011-02-17 Unhwa Isolated population of plant single cells and method of preparing same
US8329471B2 (en) 2005-10-31 2012-12-11 Unhwa Corporation Isolated population of plant single cells and method of preparing same
US20100233813A1 (en) * 2007-09-21 2010-09-16 Unhwa Corporation Plant stem cell line derived from cambium of herbaceious plant with storage root and method for isolating the same
US8247230B2 (en) 2007-09-21 2012-08-21 Unhwa Corporation Plant stem cell line derived from cambium of herbaceous plant with storage root and method for isolating the same
US9095532B2 (en) 2008-06-13 2015-08-04 Unhwa Corporation Composition for anti-aging or antioxidant composition containing plant stem cell line derived from cambium or Panax ginseng including wild ginseng and ginseng as active components
US9289457B2 (en) 2008-08-14 2016-03-22 Unhwa Coproration Composition for preventing or treating liver diseases, containing plant stem cell lines derived from the cambium of Panax ginseng including mountain ginseng or ginseng as active ingredient
US20110217273A1 (en) * 2008-09-30 2011-09-08 Unhwa Corporation Composition for Preventing or Treating AIDS Containing Plant Stem Cell Line Derived from Cambium of Panax Ginseng Including Wild Ginseng or Ginseng as Active Ingredient
US9415081B2 (en) 2008-09-30 2016-08-16 Unhwa Corporation Composition for preventing or treating AIDS containing plant stem cell line derived from cambium of Panax ginseng including wild ginseng or ginseng as active ingredient
US10463603B2 (en) 2012-01-05 2019-11-05 L'oreal Cosmetic use of dedifferentiated plant cells
CN110870562A (zh) * 2018-08-29 2020-03-10 株式会社爱茉莉太平洋 用于增强皮肤弹性或改善皮肤皱纹的包含人参细胞裂解物的组合物

Also Published As

Publication number Publication date
CN102159182B (zh) 2014-09-03
CA2732058A1 (en) 2009-12-17
CN102159182A (zh) 2011-08-17
US20130302287A1 (en) 2013-11-14
WO2009151302A9 (ko) 2010-06-10
US9095532B2 (en) 2015-08-04
JP2011522884A (ja) 2011-08-04
KR101126315B1 (ko) 2012-03-23
RU2011100824A (ru) 2012-08-10
CA2732058C (en) 2014-09-23
EP2308462A2 (en) 2011-04-13
AU2009258386A1 (en) 2009-12-17
RU2500386C2 (ru) 2013-12-10
WO2009151302A2 (ko) 2009-12-17
WO2009151302A3 (ko) 2010-03-11
KR20090129963A (ko) 2009-12-17
JP5572786B2 (ja) 2014-08-20
AU2009258386B2 (en) 2013-04-04
BRPI0909876A2 (pt) 2020-09-01

Similar Documents

Publication Publication Date Title
US9095532B2 (en) Composition for anti-aging or antioxidant composition containing plant stem cell line derived from cambium or Panax ginseng including wild ginseng and ginseng as active components
US9585923B2 (en) Antioxidant, anti-inflammatory or anti-aging composition containing taxus cambium- or procambium-derived cell line as active ingredient
CN109069407B (zh) 具有增加的没食子酸含量的莲愈伤组织提取物，其制备方法和含有其的美白化妆品组合物
KR102381564B1 (ko) 한국산 산삼 캘러스 세포배양에 의하여 얻어진 고수율 진세노사이드 생합성유도 조성물 및 이의 용도
KR101420211B1 (ko) 새싹추출물 및 새순추출물을 이용한 피부 외용제 조성물
US11096885B2 (en) Composition for enhancing skin elasticity or improving skin wrinkles comprising ginseng cell lysate
KR20120057370A (ko) 은행나무과의 형성층 유래 식물줄기세포를 유효성분으로 함유하는 항노화용 조성물
CN107523532A (zh) 一种去分化植物细胞培养物及其在化妆品中的应用
EP3980123B1 (fr) Extrait de graines de moringa peregrina riche en 2,5-diformylfuran, son procédé d'obtention et son utilisation dans des compositions cosmétiques
KR102298449B1 (ko) 포포나무 추출물 및 록샘파이어의 캘러스 배양물인 줄기세포 스템셀을 포함하는 화장료 조성물
KR101107925B1 (ko) 토마토 캘러스 추출물을 함유하는 화장료 조성물
KR20210141271A (ko) 갯질경을 유효성분으로 포함하는 피부세포재생용 조성물
KR20110033461A (ko) 백화사설초의 줄기세포를 함유하는 항산화 및 항노화용 화장료 조성물
KR20150090014A (ko) 튤립나무 태좌 세포 배양 추출물을 함유한 항노화 피부 외용제 조성물
CN113631227A (zh) 抗老化剂、抗氧化剂、抗炎剂、及美白剂、以及化妆品
KR101291460B1 (ko) 섬오갈피나무의 캘러스 추출물을 함유하는 피부 외용제 조성물
KR102374884B1 (ko) 황칠나무 추출물 및 산양삼 추출물을 유효성분으로 포함하는 화장료 조성물
WO2023042826A1 (ja) ブナ科植物由来カルス、カルス抽出物、それを用いた方法および化粧品組成物
KR20170039870A (ko) 서울오갈피 배아 줄기세포 추출물을 유효성분으로 함유하는 화장료 조성물
KR101593905B1 (ko) 산삼세포의 이차 대사산물 생성 촉진방법
KR20240020034A (ko) 알로에 형성층 유래 알로에 줄기세포 추출물의 제조방법 및 이에 따라 제조된 추출물을 포함하는 피부 항산화 조성물
CN114588100A (zh) 大量含有愈伤组织代谢产物的愈伤组织溶解产物及其制备方法
KR20010106527A (ko) 생약식물의 추출물을 유효성분으로 하는 미백화장료제조방법
OA21067A (fr) Extrait de graines de Moringa Peregrina riche en 2,5-diformylfuran, son procédé d'obtention et son utilisation dans des compositions cosmétiques.
JP2022084148A (ja) 高含有量のカルス代謝産物を有するカルス溶解物およびその製造方法

Legal Events

Date Code Title Description
AS Assignment

Owner name: UNHWA CORPORATION, KOREA, REPUBLIC OF

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:JANG, MI OK;LIM, MIN JUNG;OH, IL SEOK;AND OTHERS;REEL/FRAME:025635/0030

Effective date: 20101223

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION